The Architecture of Access: How Organ Allocation Systems Disproportionately Affect Women

The Architecture of Access: How Organ Allocation Systems Disproportionately Affect Women

Organ transplantation remains one of modern medicine’s most complex resource-allocation systems. While survival rates for recipients have improved significantly, structural inequities persist in how patients are prioritized for deceased and living donor organs. Emerging analyses published throughout 2024 and early 2025 increasingly highlight that sex and gender differences—notably skeletal physiology, biochemical baselines, and sociocultural roles—can unintentionally skew clinical pathways and waitlist outcomes for women. Understanding these mechanisms is critical for clinicians, policymakers, and patients navigating transplant care as regulatory frameworks undergo systematic review.

Current evidence points to two primary axes of disparity: algorithmic scoring systems used for deceased donor prioritization, and referral or evaluation patterns in living donation networks. Both areas reflect broader challenges in designing universal medical metrics that account for physiological diversity without introducing systematic bias.

Algorithmic Confounders in Liver Transplant Priority

In the United States and across Eurotransplant jurisdictions, deceased donor livers are allocated primarily using the Model for End-Stage Liver Disease (MELD) score. This system calculates urgency based on objective laboratory values, including bilirubin, sodium, and serum creatinine. However, serum creatinine—a byproduct of normal muscle metabolism—introduces a well-documented biological confounder. Because women generally possess lower skeletal muscle mass than men, their baseline creatinine levels tend to be lower even when renal function or overall physiological decline is clinically equivalent.

Consequently, women frequently receive lower MELD scores than men with comparable or more advanced disease severity. Research published in Transplant International (January 2025) demonstrates that while women comprise approximately 33 percent of patients presenting with severe end-stage liver disease, they represent only roughly 31 percent of recipients^[1]. Longitudinal analyses in the American Journal of Transplantation further confirm that across most MELD-Na thresholds, women exhibit significantly reduced estimated survival without transplantation compared to men^[3]. Eurotransplant registry data from 2024 corroborate these trends, showing that females undergo transplantation at lower frequencies than males when matched at equivalent listing scores^[6].

These discrepancies translate directly into longer wait times and elevated waitlist mortality. When an algorithmic priority system relies on a biomarker inherently influenced by sex-specific musculoskeletal baselines, the downstream effect is delayed access to life-saving intervention.

Iterative Reform and the Limits of MELD 3.0

Recognizing these limitations, the United Network for Organ Sharing (UNOS) and the Organ Procurement and Transplantation Network (OPTN) implemented MELD 3.0 to refine risk stratification. The updated framework incorporates serum bilirubin and sodium alongside a revised estimated glomerular filtration rate (eGFR) calculation designed to reduce muscle-mass bias. Notably, it also introduces B-type Natriuretic Peptide (BNP) to better capture cardiac risk, a leading cause of mortality on the liver transplant waitlist.

Early performance evaluations suggest that MELD 3.0 successfully improves mortality prediction and narrows certain sex-based gaps. However, recent peer-reviewed assessments caution that structural disparities remain. Studies featured in Hepatology (October 2025) and Frontiers Partnerships (January 2025) indicate that the mathematical interplay between albumin and creatinine within the formula continues to disadvantage patients with smaller body frames, disproportionately impacting many women^[2]. Furthermore, while algorithmic transparency has increased, sex gaps in access to early transplantation persist, underscoring that technical revisions alone cannot fully resolve physiologically rooted scoring inequities.

Because policy adjustments are still being validated through real-world outcome tracking, clinicians currently face a period of transitional calibration. Uncertainty persists regarding long-term equity gains, and ongoing monitoring by transplant societies remains essential.

Referral Pathways and Asymmetry in Kidney Transplantation

Systemic disparities extend beyond deceased donor algorithms into the foundational step of clinical referral. In kidney transplantation, a pronounced demographic imbalance exists among living donors. Globally, 55 to 65 percent of living donors identify as women, a pattern frequently attributed to sociocultural expectations, familial caregiving responsibilities, and gendered altruism^[4]. Paradoxically, despite contributing heavily to the living donation supply chain, women are significantly less likely to receive kidney transplants themselves.

Evidence compiled in Kidney Reports indicates that women face delays and lower rates of specialist referral, evaluation completion, and successful match placement compared to male counterparts^[4]. Qualitative investigations conducted in 2025 and 2026 reveal that power dynamics within family units often steer female relatives toward donation rather than recipient prioritization, while blood type and histocompatibility probabilities compound referral barriers in localized donor pools.

This disconnect highlights a critical gap in equitable care navigation: the pipeline from initial nephrology assessment to waitlist entry requires deliberate auditing to ensure that gendered social pressures do not inadvertently delay or divert women from receiving appropriate transplant evaluation.

Navigating Policy Shifts and Clinical Advocacy

In response to accumulating evidence, regulatory bodies including HRSA and OPTN have initiated comprehensive reviews targeting single-organ allocation tables. As outlined in February 2026 governance documents, the agency is developing a Comprehensive Multi-Organ Allocation Policy aimed at systematically identifying and mitigating algorithmic biases across transplant frameworks^[5]. These initiatives mark a significant shift toward standardized equity auditing, though implementation timelines vary by region and organ type.

For clinicians, current best practice involves maintaining heightened awareness of physiological baselines when interpreting automated risk scores. If a patient’s clinical trajectory or physical examination contradicts an algorithmic output, manual chart review and multidisciplinary discussion should be prioritized before finalizing allocation decisions. Patients and advocates are encouraged to ask explicit questions regarding referral timelines, alternative evaluation metrics, and the possibility of manual score reconsideration when laboratory values may not fully reflect functional status.

While regulatory modernization promises greater equity, implementation phases inevitably introduce variables that require continuous outcome tracking. Transparency around module performance across diverse demographic cohorts will determine whether these policy shifts achieve their intended corrective effect. Until prospective, multi-center trials validate long-term impacts, vigilant clinical documentation and patient-centered advocacy remain vital safeguards against systemic oversight in women’s transplant care.